SNPX News and Press, Synaptogenix Inc. From 09/10/21

Synaptogenix Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference PR Newswire NEW YORK , Sept. 10, 2021 /PRNewswire/ -- Synaptogenix, Inc (Nasdaq: SNPX), an emerging biopharmaceutical company developing regenerative therapeutics...

Synaptogenix Signs Memorandum Of Understanding with Nemours A.I. DuPont Hospital to Initiate Trial Using Bryostatin, Under Orphan Drug Status, to Treat Fragile X Syndrome - Bryostatin-1 to benefit from previously granted Orphan Drug Status for the treatment of Fragile X syndrome...

Gainers: Tyme Technologies TYME +46%, Xenetic Biosciences XBIO +40%, IMV (IMV) +18%, Translate Bio (TBIO) +10%, Reviva Pharmaceuticals (RVPH) +9%.Losers: ATI Physical Therapy ATIP -40%, Iterum Therapeutics ITRM -36%, Intec Pharm...

Synaptogenix Discloses Positive Results of Further Bryostatin Trial Analyses in Presentation at Alzheimer's Association International Conference 2021 - Presentation entitled: "Bryostatin Restores Cognitive Functions Above Baseline in Advanced Alzheimer's Disease (AD) Patients: A...

India Globalization Capital (IGC) +128% announces issuance of Patent for the treatment of Alzheimer’s disease using THCPainReform (PRFX) +51%.ImmunoPrecise Antibodies IPA +41% highlights new data from TATX-03 SARS-CoV-2 Delta studySequential Brands (SQBG) +28%.NeuroMetri...

Synaptogenix Announces Conference Call to Discuss AAIC Abstract Findings PR Newswire NEW YORK , July 21, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative disea...

Synaptogenix to Present Data at Alzheimer's Association International Conference 2021 Highlighting Bryostatin Restores Cognitive Function Above Baseline PR Newswire NEW YORK , July 14, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging bioph...

Synaptogenix ([[SNPX]] +1.7%) announces that a new patent has been awarded by the U.S. Patent and Trademark Office in relation to the treatment of Alzheimer's disease.Patent number 16/914,399 is entitled: Methods for Inducing Synaptogenesis with Synaptic Growth Factor Activating Compounds.The...

Synaptogenix Announces Regenerative Patent Award to Treat Alzheimer's Disease PR Newswire NEW YORK , July 7, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerat...

Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network PR Newswire NEW YORK , June 24, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing thera...